The Medicines Co. (MDCO) and Roche AG unit Hoffmann-Laroche Inc. are joining the effort launched by the Office of the Assistant Secretary for Preparedness and Response, through the Biomedical Advanced Research and Development Authority (BARDA), to develop products to combat the emerging threat of multidrug-resistant bacterial infections, often referred to as superbugs. Read More
Reports of a fifth patient experiencing immune-related adverse events is prompting Mirna Therapeutics Inc. to close out its phase I trial testing microRNA mimic MRX34 and to "reassess where we stand with our pipeline now," according to President and CEO Paul Lammers, a disclosure that sent shares of Mirna (NASDAQ:MIRN) down 47 cents, or 19 percent, to close Wednesday at $2. Read More
As evidenced most recently by Allergan plc's purchase of Tobira Therapeutics Inc. and Akarna Therapeutics Ltd., nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are getting a lot of love from the pharma industry these days, with good reason. (See BioWorld Today, Sept. 21, 2016.) Read More
CEO Stephen Hurly told BioWorld Today that Viventia Bio Inc.'s bid to lift antibody-drug conjugates (ADCs) "to the next level" in oncology powered a merger deal with Eleven Biotherapeutics Inc., a peer in protein engineering that's had some stumbles developing ophthalmology therapies. Read More
DUBLIN – GE Healthcare Life Sciences' $150 million investment in the creation of GE Biopark Cork, which it unveiled this week, is its first foray into building a prefabricated, off-the-shelf biomanufacturing facility that will cater to multiple tenants. Read More
Capricor Therapeutics Inc., of Los Angeles, said it closed its public offering of about 3.1 million shares priced at $3.20 each and concurrent registered direct offering of 312,500 shares sold to Cedars-Sinai Medical Center for $3.20 per share. Read More
Symbiotix Biotherapies Inc., of Boston, said it received a $2 million phase II Small Business Technology Transfer award from the National Institute of Diabetes and Digestive and Kidney Diseases to develop its molecular therapeutics from the human microbiome. Read More
Epizyme Inc. and Foundation Medicine Inc., both of Cambridge, Mass., formed a collaboration to support patient identification and enrollment in Epizyme's ongoing phase II trial of tazemetostat to treat non-Hodgkin lymphoma (NHL). Read More
